Literature DB >> 26377617

Pharmacodynamic models of age-structured cell populations.

Wojciech Krzyzanski1.   

Abstract

The purpose of this work is to review basic pharmacodynamic (PD) models describing drug effects on cell populations and expand them to age-structured models using the theory of physiologically structured populations. The plasma drug concentrations are interpreted as the environment affecting the cell production and mortality rates. An explicit solution to model equations provides the age density distribution that serves to establish a relationship between the cell lifespan distribution and the hazard of cell removal. Given the lifespan distributions, the age distributions for most commonly applied PD models of cell responses including basic cell turnover, transit compartments, and basic lifespan models have been derived both for the baseline conditions and drug treatment. The steady-state age distribution for basic indirect response models is exponential, and it is uniform for the basic lifespan model. As an example of more complex cell population, the age distribution of human red blood cells has been simulated based on a recent model of red blood cell survival. The age distribution for cells in the transit compartment model is the sum of the gamma functions. Means and variances of age distributions for all discussed models were calculated. A brief discussion of numerical challenges and possible future model developments is presented.

Entities:  

Keywords:  Age structure; Cell population; Lifespan distribution; Mortality rate; Pharmacodynamic model

Mesh:

Substances:

Year:  2015        PMID: 26377617     DOI: 10.1007/s10928-015-9446-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  26 in total

1.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

Authors:  L A Harker; L K Roskos; U M Marzec; R A Carter; J K Cherry; B Sundell; E N Cheung; D Terry; W Sheridan
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

Authors:  Lorin K Roskos; Peggy Lum; Pamela Lockbaum; Gisela Schwab; Bing-Bing Yang
Journal:  J Clin Pharmacol       Date:  2006-07       Impact factor: 3.126

4.  Solution and implementation of distributed lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

5.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

6.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

Review 7.  Multiple-pool cell lifespan model of hematologic effects of anticancer agents.

Authors:  Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

8.  Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-14       Impact factor: 2.745

Review 9.  Deciphering death: a commentary on Gompertz (1825) 'On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies'.

Authors:  Thomas B L Kirkwood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-19       Impact factor: 6.237

10.  Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Daniel J Coffield; Micha Levi; Patrick Smith; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2013-03-14       Impact factor: 4.475

View more
  3 in total

1.  Perspectives on the history and scientific contributions of Gerhard Levy.

Authors:  Ho-Leung Fung; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-24       Impact factor: 2.745

2.  Age-structured population model of cell survival.

Authors:  Wojciech Krzyzanski; Pawel Wiczling; Asfiha Gebre
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-29       Impact factor: 2.745

3.  Special issue: mathematical pharmacology.

Authors:  Wojciech Krzyzanski; J G Coen van Hasselt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-01-03       Impact factor: 2.745

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.